Boston Scientific set to storm the US stent market with NIR approval
This article was originally published in Clinica
Executive Summary
The FDA last week approved the sale of Boston Scientific's new range of NIR coronary stents. The stents are already market leaders in Europe and Japan and are expected to have a major impact on the US stent market within the first year of sales.